Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

23.10 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 3, 2025 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	3,433
Open	23.10
Bid (Size)	22.25 (200)
Ask (Size)	23.12 (100)
Prev. Close	23.10
Today's Range	23.10 - 23.10
52wk Range	19.05 - 26.58
Shares Outstanding	102,780,151
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Represents an Affordable Growth Opportunity ↗

November 29, 2025

Catalyst Pharmaceuticals offers strong growth, solid profitability, and a debt-free balance sheet, all at an attractive valuation compared to its biotech peers.

Via Chartmill

Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

November 24, 2025

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Performance

YTD	+7.3%	+7.3%
1 Month	+7.7%	+7.7%
3 Month	+16.7%	+16.7%
6 Month	-8.7%	-8.7%
1 Year	+6.4%	+6.4%

More News

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Combines Strong Growth with Bullish Technical Setup ↗

November 21, 2025

Via Chartmill

Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™

November 19, 2025

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference

November 18, 2025

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Stands Out as a Quality Investment on Caviar Cruise Screen ↗

November 17, 2025

Via Chartmill

Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

November 05, 2025

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work

November 04, 2025

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference

November 03, 2025

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Shows Strong Fundamentals and Technical Breakout Potential ↗

October 29, 2025

Via Chartmill

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Presents a Compelling Case for Affordable Growth ↗

October 27, 2025

Via Chartmill

Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025

October 22, 2025

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

What Does the Market Think About Catalyst Pharmaceuticals Inc? ↗

October 21, 2025

Via Benzinga

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Value Investment with Strong Fundamentals ↗

October 20, 2025

Via Chartmill

Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences

October 09, 2025

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Presents a Compelling Case for Affordable Growth ↗

October 02, 2025

Via Chartmill

Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program

October 01, 2025

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Value Investing Opportunity with Strong Fundamentals ↗

September 12, 2025

Via Chartmill

How Is The Market Feeling About Catalyst Pharmaceuticals? ↗

September 09, 2025

Via Benzinga

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Emerges as a Top GARP Investment with Strong Growth and Reasonable Valuation ↗

September 09, 2025

Via Chartmill

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Stands Out as a High-Quality Caviar Cruise Candidate ↗

September 03, 2025

Via Chartmill

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

August 28, 2025

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

UPDATED- Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

August 26, 2025

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals

August 25, 2025

From Catalyst Pharmaceuticals, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Catalyst Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Catalyst Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Catalyst Pharmaceuticals, Inc. - Common Stock trade on?

Catalyst Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Catalyst Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Catalyst Pharmaceuticals, Inc. - Common Stock is CPRX on the Nasdaq Stock Market

What is the current price of Catalyst Pharmaceuticals, Inc. - Common Stock?

The current price of Catalyst Pharmaceuticals, Inc. - Common Stock is 23.10

When was Catalyst Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Catalyst Pharmaceuticals, Inc. - Common Stock was at 12/03/25 04:00 PM ET

What is the market capitalization of Catalyst Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Catalyst Pharmaceuticals, Inc. - Common Stock is 2.37B

How many shares of Catalyst Pharmaceuticals, Inc. - Common Stock are outstanding?

Catalyst Pharmaceuticals, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.